Expanded Access Study of Melphalan CS-PHP with Delcath System in Patients With Ocular/Cutaneous Melanoma Mets to Liver

The safety and efficacy of CS-PHP-melphalan has been evaluated in a phase 3 trial conducted in the same patient population as well as using the same melphalan dosing as proposed in this study. This expanded access protocol will provide an experimental alternative treatment option for both physicians and patients until the Delcath CS-PHP System receives marketing approval.

Pill Graphic

Clinical Bibliography

Browse through our online library of published articles and abstracts.

Start Now


Delcath does not make any claim whatsoever, real or implied, about the efficacy or safety of any therapy, drug, system, or technique under active research.